Patents Issued in March 18, 2021
  • A STABLE ORAL PHARMACEUTICAL COMPOSITION OF FERRIC CITRATE
    Publication number: 20210077451
    Abstract: The present invention relates to a pharmaceutical composition of ferric citrate or a pharmaceutically acceptable salt and one or more pharmaceutically acceptable excipients. The present invention specifically relates to oral pharmaceutical composition of ferric citrate and one or more pharmaceutically acceptable excipients. Further, the present invention relates to stable pharmaceutical composition of ferric citrate or a pharmaceutically acceptable salt which improves patient compliance by enhancing ease of administration of the above mentioned pharmaceutical composition. Moreover, the present invention describes the methods employed for manufacturing the above mentioned oral pharmaceutical composition of ferric citrate.
    Type: Application
    Filed: December 31, 2018
    Publication date: March 18, 2021
    Inventors: Parva Yogeshchandra PUROHIT, Paras Rasiklal VASANANI, Ashokkumar Hajabhai BARIA, Hinal Nitinkumar PATEL, Krunal Ashokbhai GOYANI
  • TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION
    Publication number: 20210077452
    Abstract: The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers.
    Type: Application
    Filed: May 7, 2020
    Publication date: March 18, 2021
    Inventors: James SHANAHAN, Peter CORNELIUS
  • INHIBITORS OF GLUCOSYLCERAMIDE DEGRADATION IN THE TREATMENT OF DISEASES OF THE MOTOR UNITS
    Publication number: 20210077453
    Abstract: Inhibitors of glucosylceramide degradation, to pharmaceutical compositions containing same and to the use of same in the treatment of diseases of the motor units, such as amyotrophic lateral sclerosis.
    Type: Application
    Filed: September 29, 2020
    Publication date: March 18, 2021
    Inventors: Michael SPEDDING, Alexandre HENRIQUES, Jean-Philippe LOEFFLER
  • TRANSFORMATION OF CANNABINOL AND TERPENE OILS INTO WATER SOLUBLE DRY POWDERS FOR SOLID FORM SUBLINGUAL DELIVERY
    Publication number: 20210077454
    Abstract: A composition includes a clathrate compound that has guest molecules and carrier molecules that trap the guest molecules. The carrier molecules are a saccharide and the guest molecules include at least one of a cannabinoid or a terpene. The clathrate compound includes, by combined weight of the carrier molecules and the guest molecules, at least 18% of the guest molecules.
    Type: Application
    Filed: January 11, 2019
    Publication date: March 18, 2021
    Inventors: John Althaus, Stephen Goldner
  • USE OF CANNABINOIDS IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER
    Publication number: 20210077455
    Abstract: The present invention relates to the use of cannabinoids in the treatment of a neurodegenerative disease or disorder. In particular the cannabinoids cannabidiolic acid (CBDA) and cannabidivarin (CBDV) were able to produce neuroprotective effects in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with amyotrophic lateral sclerosis (ALS). Furthermore, the combination of the cannabinoid tetrahydrocannabinol (THC) with the drug olexisome provided a synergistic disease modifying effect in a mouse model of neurodegenerative disease. In particular these effects were associated with the symptoms associated with ALS.
    Type: Application
    Filed: July 10, 2018
    Publication date: March 18, 2021
    Applicant: GW Research Limited
    Inventors: Benjamin Whalley, William Hind, Royston Gray, Javier Fernandez-Ruiz, Eva De Lago, Carmen Rodriguez-Cueto, Laura Garcia-Toscano, Irene Santos-Garcia
  • Dosage Delivery Film
    Publication number: 20210077456
    Abstract: A dosage delivery film composition containing a botanical drug substance formable into a bioerodible dosage delivery film, the dosage delivery film composition including: (i) one or more of: a polymer, a plasticizer, a defoamer, or an antioxidant; (ii) a cannabinoid-cyclodextrin-terpene complex or a cannabinoid-terpene-surfactant micelle, and (iii) optionally, one or more of: a taste mask, a vasodilator, or a lipophilic vehicle to transport the botanical drug substance across the mucous membrane.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 18, 2021
    Applicant: Spartak LLC
    Inventor: Sergey Y. Chistov
  • HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION
    Publication number: 20210077457
    Abstract: Methods of using a high-dose statin for treatment of AMD in a patient can be used to regress drusen and/or drusenoid pigment epithelial detachments (PEDs), to prevent atrophy of the RPE and/or one or more photoreceptors, to prevent vision loss and/or improve visual acuity, and/or to prevent progression from dry AMD to wet AMD.
    Type: Application
    Filed: December 1, 2020
    Publication date: March 18, 2021
    Inventors: Demetrios Vavvas, Joan W. Miller
  • DIBENZOTHIOPHENE DERIVATIVES AND METHODS OF TREATING CANCER THEREWITH
    Publication number: 20210077458
    Abstract: In one aspect, the present disclosure provides a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 18, 2021
    Applicant: Saint Louis University
    Inventors: Ryan D. MCCULLA, Ankita ISOR, Christopher Kent ARNATT
  • FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS
    Publication number: 20210077459
    Abstract: Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.
    Type: Application
    Filed: November 30, 2020
    Publication date: March 18, 2021
    Inventors: Nicholas S. BODOR, John J. KOLENG, David ANGULO
  • FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS
    Publication number: 20210077460
    Abstract: Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.
    Type: Application
    Filed: November 30, 2020
    Publication date: March 18, 2021
    Inventors: Nicholas S. BODOR, John J. KOLENG, David ANGULO
  • NEW USE
    Publication number: 20210077461
    Abstract: The present invention relates to methods and pharmaceutical compositions for the prevention or in delaying time to first occurrence of mortality, in particular cardiovascular death, and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said patient.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 18, 2021
    Inventors: Victor Chengwei SHI, Martin LEFKOWITZ, Adel Remond RIZKALA
  • METHOD AND SYSTEM FOR TREATING CANCER
    Publication number: 20210077462
    Abstract: The invention provides a method for treating cancer in which a level of reduced folate carrier (RFC) or folylpolyglutamate synthetase (FPGS) in cancer cells of the biopsy is determined. If the level of RFC or FPGS in the cancer cells is below a threshold value, the cancer is treated with an inhibitor of serine-hydroxymethyltransferase (SHMT)1.
    Type: Application
    Filed: September 18, 2020
    Publication date: March 18, 2021
    Inventors: Tomer SHLOMI, Won Dong LEE
  • Methods and Combination Therapy to Treat Cancer
    Publication number: 20210077463
    Abstract: This invention relates to a method of treating cancer by administering a combination therapy comprising a combination of a MEK inhibitor and a PD-1 axis binding antagonist, or a combination of a MEK inhibitor and a PARP inhibitor, or a combination of a MEK inhibitor and a PD-1 axis binding antagonist and a PARP inhibitor to a patient in need thereof.
    Type: Application
    Filed: December 17, 2018
    Publication date: March 18, 2021
    Inventors: Christoffel Hendrik Boshoff, Rossano Cesari, Cristian Massacesi, Nuzhat Pathan, Patrice A. Lee, Shannon L. Winski
  • NOVEL ANTI-FUNGAL INHIBITORS
    Publication number: 20210077464
    Abstract: Described herein are methods of treating or preventing a fungal infection by administering one or more compounds of the present invention to a subject. The methods of the present invention treat or prevent a fungal infection of C. neoformans, C. gattii, L. prolificans, C. albicans, or a combination thereof, as examples. The compounds of the present invention may be administered to a subject with other agents such as antifungal agents.
    Type: Application
    Filed: December 12, 2018
    Publication date: March 18, 2021
    Inventors: Jürgen Bosch, Arturo Casadevall, Eric H. Jung
  • ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS
    Publication number: 20210077465
    Abstract: Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 18, 2021
    Inventors: Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
  • ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS
    Publication number: 20210077466
    Abstract: Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 18, 2021
    Inventors: Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
  • Methods of Preventing Cardiovascular Events in Residual Risk Dyslipidemic Populations
    Publication number: 20210077467
    Abstract: The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 18, 2021
    Inventors: Ryu Oshima, Gary Gordon
  • PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING
    Publication number: 20210077468
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Application
    Filed: October 30, 2020
    Publication date: March 18, 2021
    Inventors: Philip Stewart Low, Sumith A. Kularatne
  • PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20210077469
    Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: (I?), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: March 18, 2021
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS
    Publication number: 20210077470
    Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.
    Type: Application
    Filed: August 3, 2020
    Publication date: March 18, 2021
    Inventors: Sergio Lociuro, Stefano Biondi, Glenn E. Dale, Marilyne Bourotte, Marc Gitzinger
  • RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS
    Publication number: 20210077471
    Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.
    Type: Application
    Filed: August 3, 2020
    Publication date: March 18, 2021
    Inventors: Glenn E. Dale, Sergio Lociuro, Christian Kemmer, Vincent Trebosc, Marc Gitzinger
  • ANTIBIOTIC COMBINATION THERAPIES
    Publication number: 20210077472
    Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.
    Type: Application
    Filed: August 3, 2020
    Publication date: March 18, 2021
    Inventors: Vincent Trebosc, Christian Kemmer, Glenn E. Dale, Sergio Lociuro, Marc Gitzinger
  • COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF
    Publication number: 20210077473
    Abstract: Methods of treatment of addiction and/or dependence, methods of promoting cessation of various addictions, such as smoking and/or vaping, and methods of promoting a reduction in various addictions, such as smoking and/or vaping, uses of cytisine as an addiction cessation treatment, and dosage regimens for the foregoing are provided.
    Type: Application
    Filed: August 14, 2020
    Publication date: March 18, 2021
    Inventors: Cindy A. Jacobs, Daniel F. Cain, Anthony Clarke
  • FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE
    Publication number: 20210077474
    Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.
    Type: Application
    Filed: August 25, 2020
    Publication date: March 18, 2021
    Inventors: Mark REYNOLDS, Charles Todd EARY
  • COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF
    Publication number: 20210077475
    Abstract: Methods of treatment of addiction and/or dependence, methods of promoting cessation of various addictions, such as smoking and/or vaping, and methods of promoting a reduction in various addictions, such as smoking and/or vaping, uses of cytisine as an addiction cessation treatment, and dosage regimens for the foregoing are provided.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 18, 2021
    Inventors: Cindy A. Jacobs, Daniel F. Cain, Anthony Clarke
  • COMPOSITION OR METHOD INCLUDING (T)EW-7197 FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL DISEASES
    Publication number: 20210077476
    Abstract: The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.
    Type: Application
    Filed: December 13, 2018
    Publication date: March 18, 2021
    Applicants: THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Noriko KOIZUMI, Naoki OKUMURA, Mayumi YAMAMOTO
  • MICROGLIA MODULATORS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20210077477
    Abstract: The present invention relates to methods for treating a depression condition in a subject, including administering to the subject at least one microglial modulator or a combination thereof. Further provided are methods using a microglial modulator(s) in combination with non-invasive brain stimulation (NIBS), such as electroconvulsive therapy (ECT).
    Type: Application
    Filed: March 27, 2019
    Publication date: March 18, 2021
    Inventor: Raz YIRMIYA
  • METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS
    Publication number: 20210077478
    Abstract: Compounds capable of activating a neuronal heteromeric nicotinic acetylcholine receptor are provided and can be administered in the form of pharmaceutical compositions of the like. Methods for using the compounds for treating, preventing, or ameliorating respiratory depression and overdose induced by an opioid, or other cause of respiratory depression are also provided. Methods of inducing analgesia, anesthesia, or sedation in a subject, while simultaneously treating, preventing, or ameliorating respiratory depression and overdose induced by an opioid, or other cause of respiratory depression are also provided.
    Type: Application
    Filed: November 21, 2018
    Publication date: March 18, 2021
    Inventors: JUN REN, JOHN J. GREER
  • FORMULATIONS OF PIMAVANSERIN
    Publication number: 20210077479
    Abstract: Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
    Type: Application
    Filed: August 27, 2018
    Publication date: March 18, 2021
    Inventors: Ravi Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
  • NANOPARTICLE FORMULATIONS OF DECOQUINATE IN THE FORM OF SOLID SOLUTION
    Publication number: 20210077480
    Abstract: Hot-melt extrusion for producing solid solution comprising nanoparticle formulation of decoquinate is disclosed. Aqueous phase comprising the nanoparticles of hot-melt extruding products is homogeneous and stable. Provided is the composition comprising the solid solution of decoquinate and a method of hot-melt extrusion for producing this composition comprising the solid dispersion of decoquinate. Furthermore, provided is the solid solution comprising nanosized decoquinate formulation having improved water solubility and enhanced delivery of decoquinate in digestive system for absorption, increasing bioavailability, and the efficacy against malaria at the liver stage.
    Type: Application
    Filed: January 2, 2019
    Publication date: March 18, 2021
    Inventors: Hongxing Wang, Shuanghong Liang, Yinzhou Fan, Zhenping Huang, Siting Zhao, Li Qin, Xiaoping Chen
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20210077481
    Abstract: The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.
    Type: Application
    Filed: November 30, 2020
    Publication date: March 18, 2021
    Applicant: Kyowa Kirin Co., Ltd.
    Inventors: Hiroki HANIUDA, Sachiko ENOKIZONO, Tomoyuki NAKAZATO, Takuya TOKUDA, Norie FUJIKI
  • CAMPTOTHECIN DERIVATIVES
    Publication number: 20210077482
    Abstract: Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this disclosure relates to novel camptothecin derivatives thereof, intermediates thereof, conjugates thereof, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents (anticancer agents).
    Type: Application
    Filed: September 25, 2020
    Publication date: March 18, 2021
    Inventors: Ravi V.J. Chari, Wayne C. Widdison, Wei Li, David P. Pleynet
  • BUPROPION AS A MODULATOR OF DRUG ACTIVITY
    Publication number: 20210077483
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 18, 2021
    Inventor: Herriot Tabuteau
  • ABUSE DETERRENT COMPOSITIONS AND METHODS OF MAKING SAME
    Publication number: 20210077484
    Abstract: This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.
    Type: Application
    Filed: November 25, 2020
    Publication date: March 18, 2021
    Applicant: Acura Pharmaceuticals, Inc.
    Inventors: Vijai KUMAR, David DIXON, Divya TEWARI, Dilip B. WADGAONKAR
  • PHARMACEUTICAL COMPOSITIONS OF NILOTINIB
    Publication number: 20210077485
    Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 18, 2021
    Applicant: SLAYBACK PHARMA LLC
    Inventors: Paras P. Jain, Ajay Kumar Singh, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Sandeep Jain, Hanimi Reddy Bapatu
  • Method for Treating Diseases Using SMARCA2/4 Degraders
    Publication number: 20210077486
    Abstract: The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 18, 2021
    Applicant: Aurigene Discovery Technologies Limited
    Inventors: Muralidhara Ramachandra, Leena Khare Satyam, Sanjita Sasmal, Susanta Samajdar
  • PHARMACEUTICAL COMPOSITION CONTAINING HDAC6 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF ITCHING
    Publication number: 20210077487
    Abstract: The present invention relates to a pharmaceutical composition containing an HDAC6 inhibitor as an active ingredient for prevention or treatment of itching. The present invention provides a novel pharmaceutical composition containing, as an active ingredient, an inhibitor for inhibiting an HDAC6 enzyme, and thus can effectively inhibit and treat itching caused by trypsin, tryptase, histamine, antimycin A, chloroquine, or the like.
    Type: Application
    Filed: November 15, 2018
    Publication date: March 18, 2021
    Inventors: Jun Ho Jang, Jeong Ah Yoon
  • LINEAR GLYCOSIDASE INHIBITORS
    Publication number: 20210077488
    Abstract: Compounds of formula (I), wherein A, R, W, Q, L, n and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Application
    Filed: August 24, 2017
    Publication date: March 18, 2021
    Inventors: Anna QUATTROPANI, Santosh S. KULKARNI, Awadut Gajendra GIRI
  • 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF
    Publication number: 20210077489
    Abstract: The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high JAK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is a use of the present compound or pharmaceutical composition in preparation of a medicament for treating autoimmune diseases or cancers.
    Type: Application
    Filed: September 20, 2018
    Publication date: March 18, 2021
    Inventors: Qiang Zhang, Yansheng Liu, Lantao Li, Xingfu Li, Chenming Hu
  • PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS
    Publication number: 20210077490
    Abstract: Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R1, R2, Ra, Rb, Rj, Rk, and Q are as defined herein.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 18, 2021
    Inventors: Giovanni Cianchetta, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20210077491
    Abstract: The present invention addresses the problem of providing a pharmaceutical composition for the prevention and/or treatment of diseases related to pulmonary fibrosis. Provided is a pharmaceutical composition for the prevention and/or treatment of diseases involving pulmonary fibrosis, in which the active ingredient is 3-[2-(5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl)phenyl]-1,2,4-oxadiazol-5(4H)-one, or a salt thereof, or a solvate of these.
    Type: Application
    Filed: December 14, 2018
    Publication date: March 18, 2021
    Applicant: Kowa Company, Ltd.
    Inventors: Kentaro Mikami, Rie Ishida, Takashi Nakagawa
  • METHODS AND COMPOSITIONS OF TREATING PANCREATIC CANCER
    Publication number: 20210077492
    Abstract: A method of treating pancreatic cancer in a patient in need thereof according to an embodiment includes administering to the patient an effective amount of a pharmaceutical composition comprising NSC232003 (DT1), NSC127716 (DAC), and one or more pharmaceutically acceptable carriers, excipients, or diluents.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 18, 2021
    Inventor: Francis Obunyakha Enane
  • POLYMORPHS OF ARRY-380, A SELECTIVE HER2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    Publication number: 20210077493
    Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5 -a]pyridin-7-yloxy)-3 -methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.
    Type: Application
    Filed: July 29, 2020
    Publication date: March 18, 2021
    Applicant: Array BioPharma Inc.
    Inventors: Donald T. Corson, Christopher M. Lindemann, Daniel J. Watson
  • PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR ISCHEMIA TREATMENT
    Publication number: 20210077494
    Abstract: A pharmaceutical composition for ischemia treatment of a patient includes Sildenafil and a pharmaceutically acceptable carrier. The dosage form of the pharmaceutical composition is gel, transdermal patch, cream or paste. A use of the pharmaceutical composition for ischemia treatment of a patient is disclosed.
    Type: Application
    Filed: September 16, 2019
    Publication date: March 18, 2021
    Inventor: Shu-Chi MU
  • USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER
    Publication number: 20210077495
    Abstract: The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day. The present disclosure is also directed to a pharmaceutical unit dosage composition comprising from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron for oral administration.
    Type: Application
    Filed: June 6, 2018
    Publication date: March 18, 2021
    Inventors: Stephen C. PISCITELLI, Paul MUDD
  • DOSING OF VIBEGRON FOR TREATMENT OF OVERACTIVE BLADDER
    Publication number: 20210077496
    Abstract: The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of from about 50 mg to about 100 mg (e.g., about 75 mg) of vibegron per day. The present disclosure also provides a method of treating overactive bladder comprising orally administering to a subject in need thereof a first dosage of vibegron per day for a first period and a second dosage of vibegron per day thereafter.
    Type: Application
    Filed: June 6, 2018
    Publication date: March 18, 2021
    Inventors: Stephen C. PISCITELLI, Paul MUDD
  • COMPOSITIONS AND METHODS FOR TREATING DEMENTIA WITH LEWY BODIES
    Publication number: 20210077497
    Abstract: The present invention provides methods and compositions for treatment of Dementia with Lewy Bodies.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 18, 2021
    Applicant: EIP Pharma, Inc.
    Inventor: John Jahangir Alam
  • TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION
    Publication number: 20210077498
    Abstract: This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 18, 2021
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • CHK1 (SRA737)/PARPI COMBINATION METHODS OF INHIBITING TUMOR GROWTH
    Publication number: 20210077499
    Abstract: Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer. In particular, the combination demonstrates remarkable synergistic effects on cancer cells that are representative models for tumors. Also provided for are methods for treating disorders or diseases mediated or affected by Chk1 and/or PARP activity.
    Type: Application
    Filed: April 10, 2018
    Publication date: March 18, 2021
    Inventors: Christian Andrew HASSIG, Bryan William STROUSE, Ryan James HANSEN, Kenna Lynn ANDERES
  • PIKFYVE INHIBITORS FOR CANCER THERAPY
    Publication number: 20210077500
    Abstract: The present disclosure relates methods for treating a cancer having activated MET or RAS pathway signaling using an inhibitor of PIKfyve, alone or in combination with a MET inhibitor or a RAS pathway inhibitor, and related compositions and methods to identify PIKfyve inhibitor sensitive cancers for targeted treatment.
    Type: Application
    Filed: September 10, 2020
    Publication date: March 18, 2021
    Inventors: Sean Landrette, Neil Beeharry, Peter R. Young, Jonathan M. Rothberg, Tian Xu, Henri Lichenstein